US03969K1088
© Globe Newswire
02.02.2026
ARQT
LISTED
NASDAQ
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
News Preview
WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced positive topline results from the INTEGUMENT-INFANT Phase 2 study evaluating the safety, tolerability, and effica...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
News Preview
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their p...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2026
ARQT
LISTED
NASDAQ
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
News Preview
Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Plans For Those With Chronic Inflammatory Skin Conditions...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.11.2025
ARQT
LISTED
NASDAQ
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
News Preview
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
04.11.2025
ARQT
LISTED
NASDAQ
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
News Preview
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2025
ARQT
LISTED
NASDAQ
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
News Preview
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
ARQT
LISTED
NASDAQ
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
News Preview
Arcutis today outlined its strategy to achieve sustainable growth and reported financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ARQT
LISTED
NASDAQ
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
News Preview
WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that new data demonstrating ZORYVE® (roflumilast) cream 0.15% and 0.05% improved quality of life, s...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ARQT
LISTED
NASDAQ
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
News Preview
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis’ common stock to 12 newly hired employees. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
News Preview
Arcutis today announced that it will report Q3 2025 financial results and host a virtual Investor Day on Tuesday, October 28, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ARQT
LISTED
NASDAQ
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
News Preview
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
16.09.2025
ARQT
LISTED
NASDAQ
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
News Preview
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,500 restricted stock units of Arcutis’ common stock to four newly hired employees...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
ARQT
LISTED
NASDAQ
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
News Preview
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
ARQT
LISTED
NASDAQ
Arcutis to Present at Upcoming Investor Conferences
News Preview
Arcutis today announced that management will participate in three upcoming investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis’ common stock to three newly hired employees...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis’ common stock to two newly hired employees....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
ARQT
LISTED
NASDAQ
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
News Preview
Arcutis to present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, taking place in Nashville, TN, from June 6-7, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
ARQT
LISTED
NASDAQ
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
News Preview
FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
ARQT
LISTED
NASDAQ
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
News Preview
JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3%...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.04.2025
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock units of Arcutis’ common stock to five newly hired employees...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.04.2025
ARQT
LISTED
NASDAQ
Arcutis and Padagis Agree to Stay Patent Lawsuit
News Preview
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ARQT
LISTED
NASDAQ
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age
News Preview
Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease controlRapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) Success at week 4, with significant improveme...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
ARQT
LISTED
NASDAQ
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
News Preview
Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD)....
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
ARQT
LISTED
NASDAQ
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
News Preview
Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is sharing his experience with ZORYVE® (roflumilast) topical foam, 0.3%, to help others learn more about this chronic inflammatory skin conditionZORYVE foam is a once-daily, steroid-free, topical for seborrheic dermatitis uniqu...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2025
ARQT
LISTED
NASDAQ
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
News Preview
Arcutis today announced certain preliminary unaudited financial information for the fourth quarter and full-year 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2024
ARQT
LISTED
NASDAQ
Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
News Preview
Once-daily, steroid-free foam designed to treat seborrheic dermatitis on all affected areas of the body, including hair-bearing regions such as the scalpClinical trial data show notable improvement in signs and symptoms, with the majority of patients experiencing reduced itching, scaling and redness, common burdens associated with seborrheic derm...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2024
ARQT
LISTED
NASDAQ
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
News Preview
Arcutis today announced regulatory approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.10.2024
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 95,000 restricted stock units of Arcutis’ common stock as well as options to purchase...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ARQT
LISTED
NASDAQ
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
News Preview
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
ARQT
LISTED
NASDAQ
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Arcutis today announced that management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
ARQT
LISTED
NASDAQ
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
News Preview
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
ARQT
LISTED
NASDAQ
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
News Preview
Arcutis will host a KOL virtual event July 29, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
ARQT
LISTED
NASDAQ
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
News Preview
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
ARQT
LISTED
NASDAQ
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
News Preview
Arcutis today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15%....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.05.2024
ARQT
LISTED
NASDAQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
